Letter to Orexo shareholders from Chairman Martin Nicklasson
Uppsala, Sweden – December 19, 2013 - The Chairman of Orexo, Martin Nicklasson has today sent a letter to all shareholders of Orexo AB. The letter provides an update on the launch of Zubsolv® and the progress that the product is making in the U.S. market. The letter is also available on the company's home page at www.orexo.com.
For further information, please contact:
Nikolaj Sørensen, President and CEO
Tel: +46 18-780 88 00, E-mail: firstname.lastname@example.org
Orexo is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology and commercial operations in the United States. The company is commercializing its proprietary product, Zubsolv®, for maintenance treatment of opioid dependence, in the United States. Zubsolv is a novel formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the EU and US. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ OMX Stockholm Exchange and its American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the U.S. under the symbol, “ORXOY”. The largest shareholders are Novo A/S and HealthCap.
For more information about Orexo please visit www.orexo.com.
Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Markets Act. The information was submitted for publication at 2:15 pm CET on December 19, 2013.